Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Bayer HealthCare.

Oncology Briefings™: Exploring the Role of PI3K Inhibitors for the Treatment of Hematologic Malignancies

Release Date: January 31, 2019
Expiration Date: January 31, 2020
Media: Internet - based

Activity Overview

In order to close the identified knowledge and practice gaps among oncologists and other healthcare professionals who treat and manage patients with hematologic malignancies, Physicians’ Education Resource®, LLC is proud to present this online certified CME activity titled Oncology Briefings™: Exploring the Role of PI3K Inhibitors for the Treatment of Hematologic Malignancies. The Oncology Briefings™ format is an online interactive monograph that will include an overview of diagnostic guidelines and management strategies for treatment-associated adverse events, and a review of recent data regarding current and novel therapeutic approaches in PI3K inhibitors for hematologic malignancies. National thought leaders will interpret presented data and provide key take-home points and clinical pearls for practice that will place the content into perspective.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Bayer HealthCare.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This activity is directed toward medical oncologists and hematologists who treat patients with hematologic malignancies. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the management of patients with hematologic malignancies are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Identify the subtle mechanistic characteristics of PI3K inhibitors
  • Evaluate the evidence in recent PI3K inhibitor clinical trials in the treatment of hematologic malignancies
  • Recognize the current and emerging roles of PI3K inhibition strategies across hematologic malignancies
  • Implement effective strategies for patient education and medical management for proactive mitigation of treatment-related toxicities in hematologic malignancies

Faculty, Staff, and Planners' Disclosures


Bruce D. Cheson, MD, FACP, FAAAS, FASCO
Bruce D. Cheson, MD, FACP, FAAAS, FASCO
Georgetown Lombardi Comprehensive Cancer Center
Washington, DC

Disclosures: Grant/Research Support: AbbVie, AstraZeneca, Celgene, Roche-Genentech, Pharmacyclics, Trillium, Gilead, Seattle Genetics, Bristol-Myers Squibb, TG Therapeutics; Consultant: AbbVie, Roche-Genentech, Bayer, Pharmacyclics, Gilead, Celgene, MorphoSys, Symbios, TG Therapeutics, AstraZeneca, Seattle Genetics, Karyopharm, Epizyme

Nathan H. Fowler, MD
Nathan H. Fowler, MD
Associate Professor, Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: Celgene, Janssen, Roche, Verastem; Consultant: Celgene, Janssen, Roche, Verastem, TG Therapeutics

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By